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ABSTRACT: ATP phosphoribosyltransferase (ATPPRT) cata-
lyzes the ﬁrst step of histidine biosynthesis, being allosterically
inhibited by the ﬁnal product of the pathway. Allosteric inhibition
of long-form ATPPRTs by histidine has been extensively studied,
but inhibition of short-form ATPPRTs is poorly understood.
Short-form ATPPRTs are hetero-octamers formed by four
catalytic subunits (HisGS) and four regulatory subunits (HisZ).
HisGS alone is catalytically active and insensitive to histidine. HisZ
enhances catalysis by HisGS in the absence of histidine but
mediates allosteric inhibition in its presence. Here, steady-state
and pre-steady-state kinetics establish that histidine is a non-
competitive inhibitor of short-form ATPPRT and that inhibition does not occur by dissociating HisGS from the hetero-octamer.
The crystal structure of ATPPRT in complex with histidine and the substrate 5-phospho-α-D-ribosyl-1-pyrophosphate was
determined, showing histidine bound solely to HisZ, with four histidine molecules per hetero-octamer. Histidine binding
involves the repositioning of two HisZ loops. The histidine-binding loop moves closer to histidine to establish polar contacts.
This leads to a hydrogen bond between its Tyr263 and His104 in the Asp101−Leu117 loop. The Asp101−Leu117 loop leads to
the HisZ−HisGS interface, and in the absence of histidine, its motion prompts HisGS conformational changes responsible for
catalytic activation. Following histidine binding, interaction with the histidine-binding loop may prevent the Asp101−Leu117
loop from eﬃciently sampling conformations conducive to catalytic activation. Tyr263Phe-PaHisZ-containing PaATPPRT,
however, is less susceptible though not insensitive to histidine inhibition, suggesting the Tyr263−His104 interaction may be
relevant to yet not solely responsible for transmission of the allosteric signal.
Negative feedback control is a common strategy thatevolved in many biosynthetic pathways, where the ﬁnal
biosynthetic product allosterically inhibits the ﬁrst and often
ﬂux-controlling enzyme of the pathway.1,2 The biosynthesis of
histidine showcases a classical example of negative feedback
regulation of biochemical pathways via allosteric inhibition.3
The pathway starts with the Mg2+-dependent and reversible
nucleophilic attack of adenosine 5′-triphosphate (ATP) on 5-
phospho-α-D-ribosyl-1-pyrophosphate (PRPP) to generate N1-
(5-phospho-β-D-ribosyl)-ATP (PRATP) and inorganic pyro-
phosphate (PPi), catalyzed by the ﬂux-controlling enzyme ATP
phosphoribosyltransferase (ATPPRT, EC 2.4.2.17) (Scheme
1).4 After eight subsequent reactions, PRATP is converted to
L-histidine, which allosterically inhibits ATPPRT.5
ATPPRT is a model system for interrogation of the allosteric
control of enzyme catalysis,6−11 with applications in synthetic
biology12,13 and antibiotic discovery.14,15 Accordingly, allos-
teric inhibition of ATPPRT by histidine has been extensively
investigated with the homohexameric long form of the enzyme
(HisGL), which is present in most histidine-synthesizing
organisms.3,9,14,16−18 On the other hand, inhibition of short-
form ATPPRT, found instead in archaea and some eubacteria,
is poorly understood.
Short-form ATPPRTs assemble in a hetero-octamer
consisting of four regulatory subunits ﬂanked on each side
by a dimer of catalytic subunits. The active site is found solely
within HisGS, a version of HisGL in which the C-terminal
domain responsible for allosteric inhibition is missing.8,19
HisGS on its own forms homodimers with reduced catalytic
activity, and it is insensitive to histidine.6,20 HisGS catalysis is
allosterically enhanced in the hetero-octameric ATPPRT
holoenzyme by interaction with regulatory protein HisZ, a
catalytically inactive paralogue of histidyl-tRNA synthetase
(HisRS).8,21 In the presence of histidine, however, HisZ
mediates the allosteric inhibition of ATPPRT. Only one crystal
structure of a short-form ATPPRT in complex with histidine
has been published so far, that of the thermophile Thermotoga
maritima, where, unexpectedly, eight molecules of histidine per
hetero-octamer are found, located at the HisGS−HisZ interface
and showing more polar interactions with the catalytic subunit
than with the regulatory one.22
We have recently reported the structural and kinetic basis for
allosteric activation of the hetero-octameric ATPPRT from the
psych roph i l i c bac t e r i um Psy ch roba c t e r a r c t i c u s
(PaATPPRT).10,11,20 In the work presented here, we use
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steady-state and pre-steady-state kinetics and determine the
crystal structure of the PaATPPRT−PRPP−histidine complex
to elucidate the mechanism of allosteric inhibition of short-
form ATPPRTs by histidine.
■ MATERIALS AND METHODS
Materials. ATP, PRPP, adenosine 5′-triphosphate (ADP),
L-histidine, 3-(2-thienyl)-L-alanine (TIH), MgCl2, dithiothrei-
tol (DTT), and tricine were purchased from Sigma-Aldrich. All
other chemicals were purchased from readily available
commercial sources. All chemicals were used without further
puriﬁcation. PaHisGS, PaHisZ, and Mycobacterium tuberculosis
pyrophosphatase (MtPPase) were produced as previously
published.20 The concentrations of PaHisGS, PaHisZ, and
the PaATPPRT holoenzyme were calculated as previously
described.20
PaHisGS and PaATPPRT Activity Assay. All assays were
performed under initial rate conditions in the forward direction
at 20 °C, in the presence or absence of histidine, as previously
described20 by monitoring the increase in absorbance at 290
nm due to the formation of PRATP (ε290 = 3600 M
−1 cm−1)23
in 1 cm path length quartz cuvettes (Hellma) in a Shimadzu
UV-2600 spectrophotometer. Unless stated otherwise, for
PaHisGS activity, the PaHisGS concentration was typically 2
μM, and for PaATPPRT activity, PaHisGS and PaHisZ
concentrations were 0.28 and 15 μM, respectively. Reactions
were started by addition of PRPP. Control reaction mixtures
lacked either ATP, PRPP, PaHisGS, or PaHisZ. Controls were
also carried out to ensure that the rate did not depend on
MtPPase. Initial rates were also measured with saturating
concentrations of both substrates in the presence or absence of
4 mM TIH. All kinetic measurements were performed at least
in duplicate unless stated otherwise.
Diﬀerential Scanning Fluorimetry (DSF). DSF measure-
ments (λex = 490 nm; λem = 610 nm) were performed in 96-
well plates on a Stratagene Mx3005p instrument. Thermal
denaturation of 9.4 μM PaHisZ was assayed (50 μL) in the
presence of several histidine concentrations (0−8 mM) in 100
mM tricine, 100 mM KCl, 4 mM DTT, and 15 mM MgCl2
(pH 8.5). Sypro Orange (5×) (Invitrogen) was added to all
wells. Thermal denaturation curves were recorded over a
temperature range of 25−65 °C with 1 °C min−1 increments.
Control curves without the enzyme and were subtracted from
curves with the enzyme. All measurements were carried out in
quintuplicate.
PaATPPRT Saturation Kinetics with ADP and PRPP.
Initial rates for PaATPPRT (0.28 μM) were determined at
saturating concentrations of one substrate and varying
concentrations of the other, either ADP (0.4−5.6 mM) or
PRPP (0.1−2.0 mM).
PaATPPRT Inhibition by Histidine. The half-maximal
inhibitory concentration of histidine was determined by
measuring the initial rates for PaATPPRT (0.24 μM) in the
presence of 5.6 mM ATP (or 5.6 mM ADP), 2 mM PRPP, and
varying concentrations of histidine (0−320 μM). The
inhibition mechanism was investigated by measuring the initial
rates for PaATPPRT (0.28 μM) at saturating concentrations of
one substrate and varying concentrations of the other, either
ATP (0.2−2.8 mM) or PRPP (0.1−2.0 mM), with diﬀerent
concentrations of histidine (0−10 μM). In some instances, the
lowest-concentration data point was an outlier in the double-
reciprocal plot and was excluded from the ﬁt.
Rapid Kinetics. Rapid kinetics experiments were carried
out under multiple-turnover conditions by monitoring the
increase in absorbance at 290 nm upon PRATP formation at
20 °C in an Applied Photophysics SX-20 stopped-ﬂow
spectrophotometer outﬁtted with a 5 μL mixing cell (0.5 cm
path length and 0.9 ms dead time). In all experiments, each
syringe contained 100 mM tricine (pH 8.5), 100 mM KCl, 4
mM DTT, 15 mM MgCl2, and 10 μM MtPPase. For the
approach to steady state in the PaATPPRT reaction, one
syringe carried 38 μM PaATPPRT, 4 mM PRPP, and either 0
or 60 μM histidine, while the other carried 7 mM ATP and
either 0 or 60 μM histidine. Reaction was triggered by rapidly
mixing 55 μL from each syringe. The increase in absorbance
was monitored in a split-time base for 1 s, with 2500 data
points collected before 0.2 s and 2500 in the following 0.8 s. At
least four traces were acquired for each reaction, and controls
lacked PRPP. For initial rates of PaATPPRT and PaHisGS
reactions, one syringe carried either 2−4 μM PaHisGS or 4 μM
PaATPPRT, 4 mM PRPP, and either 0 or 1.28 mM histidine,
while the other carried 11.2 mM ATP. Reaction was triggered
by rapidly mixing 55 μL from each syringe. The increase in
absorbance was monitored in a linear-time base for 10 s. At
least four traces were acquired for each reaction, with 1000
data points collected per trace. Controls lacked PRPP.
Protein Crystallography. PaATPPRT crystallization was
performed as previously described.20 Crystals were washed in a
buﬀer containing 10% polyethylene glycol 3350, 0.1 M bicine
(pH 8.5), 50 mM MgCl2, 0.1 M KBr, and 4% 1,6-hexanediol
and then soaked for 10 min a 1 μL drop of this solution in
which PRPP and ATP had been dissolved, as previously
reported.10 Crystals were then transferred to a fresh drop of
the soaking solution substituted with histidine and 20% 2-
methyl-2,4-pentanediol for 20 s and ﬂash-cooled in a stream of
nitrogen gas at 100 K. Data were collected at beamline i24 at
Scheme 1. ATPPRT-Catalyzed Reaction Is Inhibited by Histidine
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the Diamond Light Source (Oxfordshire, U.K.) and processed
using the automated processing pipeline integrated with
XDS.24 The data were scaled using AIMLESS,25 and the
structure was determined with MOLREP26 using Protein Data
Bank (PDB) entry 6FTT10 as a search model. The model,
showing the full hetero-octamer in the asymmetric unit, was
reﬁned using cycles of model building with COOT27 and
reﬁnement with REFMAC.28 Electron density in the omit map
showed the presence of histidine in the four PaHisZ subunits
and PRPP in the four PaHisGS ones. Some electron density
was seen in one of the PaHisGS chains where in previous
structures the adenine ring of ATP was observed; however, it
could not be unambiguously modeled and was left empty. The
ﬁnal coordinates were deposited in the Protein Data Bank
(entry 6R02).
Site-Directed Mutagenesis of PaHisZ. Replacement of
tyrosine for phenylalanine at position 263 of PaHisZ was
accomplished by the method of Liu and Naismith,29 with
primers 5′-GGCTTCCACTACCATACGGGTATTGTTTT-
CAACGGTTATATC-3′ and 5′-CGTATGGTAGTGGAAGC-
CGCTCAATTCGGTAACGTCAATG-3′. Successful muta-
tion was conﬁrmed by DNA sequencing (Euroﬁns Genomics).
Y263F-PaHisZ was expressed and puriﬁed by the same
protocol reported for wild-type (WT) PaHisZ.20 ESI/MS
analysis of the protein yielded a mass of 43068.9, exactly what
would be expected by the loss of a hydroxyl group when
compared with the mass of WT-PaHisZ.20 Y263F-PaHisZ-
based PaATPPRT was assayed for catalytic activity under
initial rate conditions at 20 °C in the presence of 5.6 mM ATP
and 2 mM PRPP and in the presence or absence of 320 μM
histidine, along with other reaction components exactly as
described for WT-PaATPPRT. Measurements were carried out
in duplicate.
Analysis of Kinetic and Thermal Denaturation Data.
Kinetic and DSF data were analyzed by the nonlinear
regression function of SigmaPlot 13 (SPSS Inc.). Data points
and error bars in graphs are represented as means ± the
standard error, and kinetic and equilibrium constants are
presented as means ± the ﬁtting error. Substrate saturation
data were ﬁtted to eq 1. Inhibition data at ﬁxed substrate
concentrations were ﬁtted to eq 2, and inhibition mechanism
data were ﬁtted to eq 3. In eqs 1−3, v is the initial rate, S is the
concentration of the varying substrate, kcat is the steady-state
turnover number, KM is the apparent Michaelis constant, ET is
total enzyme concentration, vi is the initial rate in the presence
of an inhibitor, IC50 is the half-maximal inhibitory concen-
tration, h is the Hill slope, Kis is the slope inhibition constant,
and Kii is the intercept inhibition constant. DSF thermal
denaturation data were ﬁtted to eq 4,30 and PaHisZ−histidine
complex equilibrium dissociation data were ﬁtted to eq 5. In
eqs 4 and 5, FU is the fraction unfolded, T is the temperature in
degrees Celsius, Tm is the melting temperature, c is the slope of
the transition region, LL and UL are folded and unfolded
baselines, respectively, Tm0 is the Tm in the absence of
histidine, Tm∞ is the Tm at an inﬁnite histidine concentration,
H is the histidine concentration, and KD is the apparent
equilibrium dissociation constant for the PaHisZ−histidine
complex.
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■ RESULTS AND DISCUSSION
Histidine Is a Noncompetitive Inhibitor of PaATPPRT.
Histidine inhibits PaATPPRT with an IC50 of 35.5 ± 0.8 μM
and an h of 1.30 ± 0.04 (Figure 1A), both values being in close
agreement with those reported for the inhibition of M.
tuberculosis HisGL ATPPRT.
17 Inhibition is noncompetitive
against both substrates (Figure 1B), and data ﬁtted to eq 3
yielded a Kis of 22 ± 6 μM and a Kii of 38 ± 7 μM against
PRPP and a Kis of 56 ± 25 μM and a Kii of 36 ± 5 μM against
ATP. Each double-reciprocal curve was also ﬁtted individually,
and linear regression of the slope and intercept replots (Figure
S1) produced a Kis of 30 μM and a Kii of 26 μM against PRPP
and a Kis of 60 μM and a Kii of 40 μM against ATP, in
reasonable agreement with those obtained from a global ﬁt to
eq 3.
Histidine is a noncompetitive inhibitor of other HisGS
ATPPRTs22,31 and of HisGL ATPPRTs,
3,16 except that from
M. tuberculosis ATPPRT, where inhibition is uncompetitive
against ATP.17 The Ki values for PaATPPRT are similar to
those reported for Campylobacter jejuni,16 M. tuberculosis,17 and
Lactococcus lactis31 ATPPRTs but nearly an order of magnitude
lower than those reported for the Salmonella typhimurium3 and
T. maritima22 enzymes.
Figure 1. PaATPPRT inhibition by histidine. (A) Dose−response curve for histidine concentration. The line is the best ﬁt of the data to eq 2. (B)
Double-reciprocal plots of substrate saturation curves in the presence of histidine. Lines are reciprocals of the best ﬁt of the data to eq 5.
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Low-Aﬃnity Binding of Histidine to Free PaHisZ. The
binding of the inhibitor to free PaHisZ was tested by DSF.
Histidine increases the Tm of PaHisZ (Figure S2A), but the
apparent aﬃnity of the inhibitor for the free regulatory subunit
is low (Figure S2B), with a KD of 2.8 ± 0.8 mM. This indicates
that PaHisGS is not strictly necessary for the binding of
histidine to PaHisZ, though the hetero-octameric arrangement
may be necessary to increase the aﬃnity of the interaction.
Catalysis and Inhibition with ADP as the Substrate.
ADP has been shown to be a substrate, replacing ATP, for
non-activated PaHisGS,
11 and the crystal structure of the
PaATPPRT−PRPP−ADP complex suggests the same may be
true for the activated enzyme.10 This hypothesis is conﬁrmed
here, with ADP eﬃciently replacing ATP as a substrate for
PaATPPRT (Figure S3A) with a kcat of 2.6 ± 0.4 s
−1, a kcat/
KM
PRPP of (3.8 ± 0.4) × 103 M−1 s−1, and a kcat/KM
ADP of (1.6
± 0.5) × 103 M−1 s−1, in ranges similar to those obtained with
ATP.20 In addition, histidine can inhibit the PaATPPRT
reaction with ADP as the substrate (Figure S3B) with an IC50
of 31 ± 1 μM and an h of 1.32 ± 0.09, in striking agreement
with the results for the reaction with ATP. This indicates that
neither catalysis nor allosteric inhibition involves the
interaction between Arg73 of PaHisGS and the γ-PO
4− group
of ATP, which is absent when ADP replaces ATP.10
Eﬀect of Histidine on the Approach to the Steady
State. PaATPPRT catalysis follows an ordered mechanism in
which PRPP binds ﬁrst to the enzyme and involves a burst of
on-enzyme PRATP formation in the ﬁrst turnover followed by
a lower steady-state rate dominated by product release.11
When ATP and histidine are rapidly mixed with PaATPPRT
Figure 2. Rapid kinetics of histidine inhibition. (A) Eﬀect of histidine−enzyme preincubation on the burst in product formation in the PaATPPRT
reaction. Dashed lines show the linear regression of the steady-state phase, and burst amplitudes are extrapolated from the y-axis intercepts. (B)
Time course of product formation from activated and non-activated PaATPPRT rapid kinetics in the presence and absence of histidine (left),
where black lines show the linear regression of the data. The bar graph (right) represents the initial rates extracted from the time courses.
Figure 3. Crystal structure of the PaATPPRT−PRPP−histidine complex. (A) Ribbon diagram of the PaATPPRT hetero-octamer found in the
asymmetric unit. (B) Omit map at 3σ showing electron density for histidine. (C) Ribbon diagram of the PaHisZ subunit with the location of the
bound histidine. PaHisGS subunits are colored cyan, and PaHisZ is colored yellow. Ligands are shown as sticks with carbon atoms matching the
color of the subunits to which they are bound.
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preincubated with PRPP (Figure 2A), the amplitude of the
burst phase, whose values are 3.49 ± 0.01 and 3.11 ± 0.01 μM
in the presence and absence of histidine, respectively, is
unchanged within experimental error. The subsequent steady-
state rates, whose values are 16.36 ± 0.01 and 7.56 ± 0.01 μM
s−1 in the absence and presence of histidine, respectively,
reﬂect the inhibition. This suggests the rates of binding of ATP
to the PaATPPRT−PRPP complex and the subsequent on-
enzyme product formation are higher than the rate of histidine
binding and establishment of inhibition. Conversely, when
ATP is rapidly mixed with PaATPPRT preincubated with
PRPP and histidine (Figure 2A), the steady-state rate (7.83 ±
0.01 μM s−1) shows the same level of inhibition but the burst
amplitude is drastically reduced to 0.53 ± 0.01 μM, conﬁrming
that histidine can establish an equilibrium with the
PaATPPRT−PRPP binary complex to inhibit the reaction
before ATP binds to trigger the ﬁrst turnover. This contrasts
with the case for M. tuberculosis ATPPRT, in which the burst
amplitude decreases when ATP and histidine are rapidly mixed
with the enzyme.17
Histidine Does Not Lead to Dissociation of PaHisGS
from PaHisZ. PaHisGS is catalytically active, albeit with
reduced activity in the absence of PaHisZ, while being
insensitive to histidine.20 Thus, the possibility that allosteric
inhibition is a result of dissociation of PaHisGS from the
PaATPPRT holoenzyme was considered, and the background
rate in the presence of histidine was that of the non-activated
PaHisGS. This was interrogated by comparing the initial rates
of activated and non-activated PaHisGS at the same
concentration in the presence and absence of histidine (Figure
2B). The rate of non-activated PaHisGS in the presence of
histidine was shown by a Student’s t test to be higher than the
rate of PaATPPRT in the presence of histidine at the p <
0.0031 level. This indicates that allosteric inhibition by
histidine does not result from release of PaHisGS from
PaATPPRT to yield the non-activated free PaHisGS rate.
Crystal Structure of the PaATPPRT−PRPP−Histidine
Complex. To gain insight into the structural underpinnings of
PaATPPRT allosteric inhibition, the 2.65 Å resolution crystal
structure of the PaATPPRT−PRPP−histidine complex was
determined, and reﬁnement statistics are listed in Table S1.
The PaATPPRT−PRPP−histidine complex crystallized in
space group P21 with a full hetero-octamer in the asymmetric
unit. Each PaHisGS molecule contained a PRRP molecule
bound in the active site in a similar arrangement as previously
found (Figure 3A).10 The omit map shows clear electron
density for one molecule of histidine (Figure 3B) bound along
the central antiparallel β-sheet of each molecule of PaHisZ
(Figure 3C), more than 18 Å from the nearest PaHisZ−
PaHisGS interface. No electron density for potential ligands
was found in the PaHisGS−PaHisZ interface.
The structure of the PaATPPRT−PRPP−histidine complex
is in sharp contrast with the only other available structure of a
HisGS ATPPRT bound to histidine, that from T. maritima, in
which two molecules of histidine per molecule of HisZ are
reported, both in the interface between the catalytic and
regulatory subunits.22 An overlay of the histidine-bound
PaHisZ structure described here with that of T. maritima
and the histidine-bound HisRS from Burkholderia thailanden-
sis32 (Figure S4) highlights the striking diﬀerences in the
location of the histidine-binding sites between the two HisZ
proteins. Interestingly, the binding position of histidine is
almost identical in PaHisZ and HisRS. The proposal that
HisRS and HisZ would share a similar location for the
histidine-binding site had been previously suggested,21 which is
now demonstrated by the current structure.
Histidine-Binding Site. The histidine-binding site is
formed solely by PaHisZ residues. The inhibitor makes several
polar interactions with the side chains of eight PaHisZ residues
(Figure 4). The α-COO− group of histidine contacts the δ-NH
and ω-NH2 groups of Arg284 and the γ-NH2 group of Gln118.
The histidine α-NH3
+ group interacts via hydrogen bonds with
the Tyr265 4-OH group and Ser308 and Thr78 β-OH groups
and via a salt bridge with the Asp76 β-COO− group. The
imidazole ring of the inhibitor is anchored to the β-strand via
an interaction between its τ-NH and Glu122 γ-COO− and
further contacts a ﬂexible loop that also includes Tyr265 via an
interaction between its π-N and His266 τ-NH. The
interactions with the imidazole ring of the inhibitor must be
essential for allosteric inhibition, because TIH, a histidine
analogue expected to bind in a manner similar to that of
histidine but whose ﬁve-membered ring does not participate in
polar interactions,9 has no eﬀect on PaATPPRT catalysis
(Figure S5). Interestingly, most PaHisZ residues responsible
for polar contacts with the allosteric inhibitor are conserved in
T. maritima HisZ (Figure S6), even though histidine is not
reported to bind to that site. Two of the residues, Tyr265 and
His266, are replaced by glutamate and tyrosine, respectively, in
T. maritima HisZ, which would still be able to make similar
interactions as seen in PaHisZ. The only signiﬁcant exception
is Arg284, which has no replacement capable of polar contacts
in the T. maritima protein.
Structural Basis for PaATPPRT Allosteric Inhibition.
HisGS ATPPRTs are intriguing hetero-octameric allosteric
systems in which HisZ mediates allosteric activation and
inhibition of catalysis by HisGS, depending on the presence of
histidine.6,8,20 The mechanism of PaATPPRT allosteric
activation has recently been uncovered and involves the
subunits of the PaHisGS dimer moving closer to one another,
leading to a change in the average position of a PaHisGS loop
that reaches across the adjacent subunit to provide leaving
Figure 4. Close-up of the histidine-binding site in PaHisZ. The
inhibitor and the relevant side chains are depicted as sticks, with
carbons colored yellow, nitrogens blue, and oxygens red. The dashed
lines represent polar contacts.
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group stabilization at the transition state via a salt bridge
between its Arg56 and the PRPP PPi moiety.
10,11 However,
this is only manifested upon binding of ATP to the
PaATPPRT−PRPP binary complex, as all other structures of
PaATPPRT, namely, the apoenzyme and the binary complexes
with PRPP and PRATP, are in a non-activated state.10 An
overlay of the crystal structures of the PaATPPRT−PRPP,
PaATPPRT−PRPP−histidine, and PaATPPRT−PRPP−ATP
(Figure 5A) complexes resulted in Cα root-mean-square
deviations (rmsds) of 0.40 Å for the ﬁrst two structures but
1.71 Å for the latter two. When the PaHisZ tetramers are
overlaid (Figure 5B), an rmsd of 0.38 Å resulted for the ﬁrst
two structures and an rmsd of 1.37 Å for the latter two. An
overlay of the PaHisGS dimers (Figure 5C) yielded an rmsd of
0.27 Å for the ﬁrst two structures and 1.75 Å for the latter two.
These results suggest that both PaATPPRT−PRPP and
PaATPPRT−PRPP−histidine complexes are in an overall
very similar non-activated conformation. However, the
PaATPPRT−PRPP complex is en route to activation upon
ATP binding, but histidine binding may lock the hetero-
octamer in a non-activated state, preventing the conforma-
tional changes that would otherwise take place following ATP
binding.
A Potential Structural Path for Allosteric Inhibition.
In an attempt to uncover how the structural rearrangements
that may prevent activation of the PaATPPRT−PRPP−
histidine complex are relayed from the inhibitor-binding site
to the active site, PaHisZ subunits from each structure
(PaATPPRT,20 PaATPPRT−PRPP, PaATPPRT−PRPP−
ATP, PaATPPRT−PRATP,10 and PaATPPRT−PRPP−histi-
dine) were overlaid over their Cα atoms (Figure 6A). The
conformations of the PaHisZ monomers are very similar across
all structures, except for the position of two loops. The ﬁrst is
the histidine-binding loop (red arrow in Figure 6A), spanning
residues Asp256−Ile269 (Figure 6B), in the PaATPPRT−
PRPP−histidine complex, which moves >4.5 Å from its
position in all other structures (Figure 6B). This loop includes
His266, whose side chain adopts a slightly diﬀerent rotamer to
interact with the inhibitor, and Tyr265, whose 4-OH group is
>6 Å from its position in the other structures, forming a
Figure 5. Overlay of the structures of PaATPPRT−PRPP, PaATPPRT−PRPP−histidine, and PaATPPRT−PRPP−ATP complexes. (A) Overlay
of the full hetero-octamers. (B) Overlay of the PaHisZ tetramers. (C) Overlay of the PaHisGS dimers.
Figure 6. PaHisZ subunit conformations across PaATPPRT structures. (A) Overlay of PaHisZ subunits from all PaATPPRT structures. The red
arrow points to the histidine-binding loop, and the blue arrow points to the Asp101−Leu117 loop. (B) Close-up view of the two loops, key side
chains, and the inhibitor histidine. PaHisZ residue side chains and bound histidine are shown as sticks. Dashed lines denote polar interactions.
Black arrows highlight the diﬀerent positions adopted by the same side chains in the diﬀerent structures.
Biochemistry Article
DOI: 10.1021/acs.biochem.9b00282
Biochemistry 2019, 58, 3078−3086
3083
hydrogen bond with the bound histidine (Figure 6B, yellow
structure). The second (blue arrow in Figure 6A) is the loop
spanning residues Asp101−Leu117 (Figure 6B), which in the
structure of the activated PaATPPRT−PRPP−ATP complex is
>2 Å from its position in all other structures (Figure 6B, gray
structure). These two loops are connected in the structure of
the PaATPPRT−PRPP−histidine complex via a hydrogen
bond between Tyr263 in the histidine-binding loop, which has
rotated almost 180° from its position in all other structures,
and His104 in the Asp101−Leu117 loop (Figure 6B). This
interaction is missing from all other PaATPPRT structures.
The Asp101−Leu117 loop leads directly to the PaHisZ−
PaHisGS interface and is poised for hydrophobic interactions
via the side chains of its Leu110 and Phe111 residues with one
of the PaHisGS monomers in the activated PaATPPRT−
PRPP−ATP complex (Figure 7, PaHisZ colored gray and
PaHisGS colored magenta). Nonetheless, in the allosterically
inhibited PaATPPRT−PRPP−histidine complex, the position
of this loop is shifted toward the other PaHisGS monomer
(Figure 7, PaHisZ colored yellow and PaHisGS colored cyan),
with PaHisZ Leu110 disrupting a Glu82−His103 interaction
in PaHisGS. Furthermore, the aromatic ring of PaHisZ Phe111
occupies a space closer to the interface between the two
PaHisGS subunits (Figure 7, PaHisZ colored yellow and
PaHisGS colored cyan), further perturbing the hydrophobic
interactions present in the activated complex (Figure 7,
PaHisZ colored gray and PaHisGS colored magenta). This
seems to have a knock-on eﬀect on several other residues along
the PaHisGS−PaHisGS interface (Figure 7, magenta and cyan),
which culminates in the α-helix and β-strand connecting the
loop responsible for cross-subunit stabilization of leaving group
departure receding (Figure 7, cyan, indicated by black arrows)
from their respective positions in the activated Michaelis
complex (Figure 7, magenta) and consequently being farther
from the adjacent catalytic subunit. This might be responsible,
in whole or in part, for the allosteric inhibition triggered by
histidine binding.
Amino acid multiple-sequence alignment of HisZs (Figure
S7) shows that Tyr263 is conserved in ﬁve sequences, and
His104 in six, of 13 aligned. In two other sequences, they are
replaced by residues capable of similar polar interactions. To
test the hypothesis about the importance of the Tyr263−
His104 interaction, the Y263F mutation was introduced into
PaHisZ (Y263F-PaATPPRT). Tyr263 is not part of the
histidine-binding site and as such should not impact histidine
binding, but the absence of the Tyr263 4-OH group will
prevent the hydrogen bond between Tyr263 and His104 from
forming. If this interaction is crucial for relaying the allosteric
signal to the active site, then Y263F-PaATPPRT should be
insensitive to inhibition by histidine. When the enzyme activity
of Y263F-PaATPPRT is measured in the absence and presence
of histidine (Figure S8), signiﬁcant but not complete inhibition
is observed. The ratio of initial rates in the presence (vi) and
absence (v0) of inhibitor (vi/v0) is 0.250 ± 0.001 for Y263F-
PaATPPRT, while vi/v0 = 0.070 ± 0.004 for WT-PaATPPRT.
This is consistent with the disruption of the Tyr263−His104
hydrogen bond rendering Y263F-PaATPPRT >3-fold less
susceptible than WT-PaATPPRT to inhibition by histidine,
raising the possibility the interaction plays a role in mediating
allostery. However, 75% of the enzyme activity of the mutant is
Figure 7. Ribbon diagram of the PaHisZ−PaHisGS and PaHisGS−PaHisGS interface in overlaid structures of PaATPPRT−PRPP−histidine and
PaATPPRT−PRPP−ATP complexes. For the sake of clarity, only part of one PaHisZ and one of the PaHisGS dimers are shown for each structure.
Side chains are shown as sticks, and substrates as wireframe. The Mg2+ ions in the structure of the PaATPPRT−PRPP−ATP complex are
represented as green spheres. Black arrows denote the distinct positions of the PaHisGS loop responsible for leaving group stabilization in the
transition state.
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still lost due to histidine inhibition, indicating that other factors
are involved in the transmission of the allosteric signal.
These elusive factors may involve additional conformational
changes triggered by histidine binding not evident in this
structure. It is worth noting that crystals of the PaATPPRT−
PRPP−histidine complex could be obtained only by soaking,
which might hinder some conformational changes due to
crystal packing. Furthermore, instead of a relatively stable
conformational change, a signiﬁcant portion of the allosteric
signal relay may involve a transient shift in the dynamic
landscape sampled by the enzyme, which would be unlikely to
be captured in crystallo. Further studies, probably encompass-
ing experimental and computational approaches, will be
required for a complete elucidation of the allosteric inhibition
pathway in short-form ATPPRTs.
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